[A clinical trial of triclabendazole in the treatment of human paragonimiasis skrjabini].
OBJECTIVE
To observe the therapeutic effect of triclabendazole in patients with paragonimiasis skrjabini.


METHODS
Four patients were treated with triclabendazole at dosage of 10 mg/kg bid for 3 days and were followed up for 6-10 months. The clinical symptoms, chest X-ray, hemogram and liver function tests were observed before and after treatment.


RESULTS
Migratory subcutaneous nodules in three patients all disappeared. Small amount of pleural effusion were absorbed in two patients. Severe headache subsided in a patient with cerebral lesion. MRI showed a bean-sized calcified spot in the right frontal region. Chest X-ray in 2 patients showed that pulmonary lesions were markedly absorbed and disappeared. There was no adverse effect of the drug.


CONCLUSIONS
Triclabendazole has marked therapeutic effect on paragonimiasis skrjabini. It is safe in administration and well tolerated.
Hu
P
P
Department of Infectious Diseases, First Affiliated Hospital, Chongqing University of Medical Sciences, Chongqing 400016.
Liu
Y H
YH
D000293:Adolescent; D000328:Adult; D000871:Anthelmintics / Q000627:therapeutic use*; D001562:Benzimidazoles / Q000627:therapeutic use*; D002648:Child; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D010237:Paragonimiasis / Q000188:drug therapy*; D016896:Treatment Outcome; D000077682:Triclabendazole
D000871:Anthelmintics; D001562:Benzimidazoles; D000077682:Triclabendazole